浙江柏拉阿图医药科技

PlatoBio is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and inflammatory diseases. The company leverages a proprietary structure-based drug design (SBDD) platform and AI-driven technologies to target complex biological pathways, with a primary focus on G protein-coupled receptors (GPCRs). Its lead candidate, PA-001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). PlatoBio aims to address significant unmet medical needs in chronic liver diseases and metabolic disorders through its robust internal R&D capabilities. The company is backed by prominent venture capital firms and maintains a growing pipeline of candidates targeting fibrosis and other metabolic conditions.